Table 4 Diagnostics (A), therapeutical interventions (B) and clinical outcomes (C) of WNV-infected patients
From: Identifying risks for severity of neurological symptoms in Hungarian West Nile virus patients
(A) Diagnostics: WNV Laboratory testing, n (%) | ||
Cerebrospinal fluid | yes | 48 (72.7) |
no | 8 (12.1) | |
data unavailable | 10 (15.2) | |
Serology | serum and CSF positive (IgG, A, M) | 62 (93.9) |
serum positive (IgG, M) | 3 (4.5) | |
serum positive (IgG: inconclusive, IgA: borderline, IgM: positive) | 1 (1.5) | |
PCR | positive | 17 (5.8) |
negative | 37 (55.9) | |
data unavailable | 10 (15.2) | |
inconclusive | 2 (3.0) | |
Lineage | lineage 2 | 17 (25.8) |
unknown (due to PCR-negative or inconclusive results) | 39 (59,0) | |
not applicable | 10 (15.2) | |
Other (relevant) Diagnostic procedures, n (%) | ||
Imaging | Confirmed alteration with CT | 10 (15.2) |
Confirmed alteration with MRI | 7 (10.6) | |
Confirmed alteration with both CT and MRI | 19 (28.8) | |
none | 24 (36.4) | |
data unavailable | 6 (9.1) | |
(B) Therapy, n (%) | ||
Antibiotic/Antiviral treatment | Antibiotic treatment | 12 (18.2) |
Antiviral treatment | 1 (1.5) | |
Antibiotic+ Antiviral treatment | 32 (48.5) | |
none | 21 (31.8) | |
Pain medication | Minor analgesics | 39 (59.1) |
Major analgesics | 3 (4.5) | |
Both minor and major analgesics | 1 (1.5) | |
none | 21 (31.8) | |
data unavailable | 2 (3.0) | |
Other relevant medication | Steroid only | 3 (4.55) |
Mannitol only | 9 (13.64) | |
Steroid + Mannitol | 13 (19.70) | |
Antiepileptics only | 3 (4.55) | |
Steroid + Mannitol + Sedative | 5 (7.58) | |
Steroid + Mannitol + medication for Dizziness | 1 (1.52) | |
Steroid + Mannitol + Sedative + Antiepileptics | 1 (1.52) | |
none | 28 (42.42) | |
Intensive Care | 9 (13.6) | |
(C) Clinical outcome, n (%) | ||
Complications (respiratory failure, hearing loss, seizures, pneumonia polyneuropathy) | 7 (10.6) | |
Death | 5 (7.6) | |
Length of hospital stay (days) | average | 10.6 |
median | 9.0 | |